Dianthus Therapeutics, Inc.

DNTH Healthcare Biotechnology

Dianthus Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, down 67.3% from fiscal 2024. In the quarter to June 2026, revenue grew 294.3%, EPS fell 2.27% and free cash flow fell 105.4%, each against the same quarter a year earlier.

72.09 2.44 −3.27%
Market cap
$4.2B
P/E
0.0×
Fwd P/E
−21.5×
Dividend yield
—
F-score
2/9
Altman Z
24.31
Beneish M
−4.75
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
4 4 2 2

+8 more TTM periods

ROE
(26.07%) (22.70%) (38.38%) (28.57%)
ROA
(24.98%) (21.77%) (35.88%) (27.12%)
ROIC
(47.74%) (132.76%) (124.80%) (60.96%)
Return on Tangible Assets
(22.26%) (16.05%) (42.83%) (32.38%)
Average Days of Receivables
20.32 336.04 9.32 592.92
Free Cash Flow per Share
(2.78) (2.72) (3.35) (2.90)
Free Cash Flow
(155.71) (130.48) (129.27) (109.63)
Other line items

Show all line items

Columns are period end dates